Bluebird bio Inc ( (BLUE) ) has released its Q3 earnings. Here is a breakdown of the information Bluebird bio Inc presented to its investors.

Welcome to bluebird bio's third quarter 2024 results conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

A team of horticulturists, bio-breeders and agriculture specialists affiliated with a host of institutions across China has ...

Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...